+1-888-308-5802     

Pfizer’s COVID-19 booster shot gets FDA approval for vulnerable groups

Author : Pankaj Singh | Published Date : 2021-09-24 

The U.S. Food and Drug Administration has approved the third dose of Pfizer/BioNTech COVID-19 vaccine for seniors and high-risk individuals. This is the first booster in the vaccination efforts of the United States.

The decision comes a month after U.S. President Biden’s announced to make the booster shots available to the public at the beginning of September. At the time, the Biden administration was criticized by scientists and public health experts for pushing boosters before finding any clear evidence regarding their necessity and before either the CDC or FDA approved their use.

Federal officials had also informed the White House that they might need to modify the booster plan as the health agencies collected and assessed the data. Since the last few weeks, experts have contested whether third doses of the Pfizer/BioNTech as well as Moderna COVID-19 vaccines were necessary or not.

The data from the U.S. and Israel seem to indicate that protection against Coronavirus infection reduces over time, though there are various estimates around how much it declines.

However, FDA’s advisory committee on vaccination voted against recommending boosters for people aged 16 and older, mentioning limited evidence for boosters in younger age groups.

The committee recommended boosters to those who are above 65 or who might be at greater risk of serious COVID-19 infection. It also approved boosters for health care workers and people with risk of exposure at work.

The decision only includes the Pfizer/BioNTech vaccine shots, and there are no revised guidelines for the Johnson & Johnson or Moderna vaccines as of now.

Centers for Disease Control and Prevention’s advisory committee is expected to meet this week and is likely to discuss whether to recommend the recently approved third shot. The committee would refine and pinpoint the groups that should qualify for the booster jabs under the FDA’s decision.

Source Credits –

https://www.theverge.com/2021/9/22/22679950/fda-covid-vaccine-booster-pfizer-older-adults

About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Klarna partners with Stripe to revolutionize retail shopping experience

Published Date: 2021-10-27         Author: Pankaj Singh

Klarna, a leading worldwide retail bank, payments, and shopping service has announced a strategic alliance with Stripe to give a better shopping experience to retail consumers. Even the retailers who are using Stripe can now use Klarna as the preferred payment option to streamline the checkout ... Read More

Calyx bags 5-year data management contract with top 10 pharma firms

Published Date: 2021-10-26         Author: Pankaj Singh

Calyx’s industry-leading RIM (Regulatory Information Management) system has reportedly been selected by the world’s top 10 pharma companies for critical submissions of clinical development data to global regulators through 2026. The five-year contract signed by the top 10 companies wi... Read More

FPT Software, IGPI join hands to digitally transform Southeast Asia

Published Date: 2021-10-25         Author: Pankaj Singh

Vietnam’s FPT Software recently announced to have partnered with Industrial Growth Platform Pte. Ltd. (IGPI Singapore) to boost digital transformation (DX) for governments, institutions, corporates, and other relevant organizations in Southeast Asia. FPT Software and IGPI Singapore, under t... Read More

© 2021 Fractovia. All Rights Reserved